Skip to main content
ILSUNG IS CO., LTD. logo

ILSUNG IS CO., LTD. — Investor Relations & Filings

Ticker · 003120 ISIN · KR7003120003 KO Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2023-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 003120

About ILSUNG IS CO., LTD.

https://www.ilsung.com/

ILSUNG IS CO., LTD. is a pharmaceutical company specializing in the development and manufacturing of therapeutic products. The company's core portfolio is focused on antibiotics, cardiovascular agents, anesthetics, and contrast media. It is actively expanding its research and development into new therapeutic areas, including treatments for gastrointestinal (GI), central nervous system (CNS), and other cardiovascular (CV) conditions.

Recent filings

Filing Released Lang Actions
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Ilsung Pharmaceuticals, covering the period from January 1, 2023, to September 30, 2023. It contains detailed financial information, management discussion, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-14 Korean
대표이사(대표집행임원)변경(안내공시)
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the resignation of a co-CEO (윤종욱) and the retention of the other CEO (윤석근) at Il-Sung Pharmaceutical. It explicitly states '대표이사(대표집행임원) 변경' (Change of Representative Director/Executive Officer). This falls directly under the definition of Board/Management Information (MANG).
2023-08-31 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This relates to the company's management of its own shares, specifically the termination of a share repurchase trust. According to the provided definitions, 'Transaction in Own Shares' (POS) covers reports of the company buying back or selling its own shares, including share repurchase programs and their status changes.
2023-08-11 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Termination of Trust Agreement' (신탁계약해지결과보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the termination of a stock trust agreement used for share buybacks and the subsequent transfer of those shares to the company's own account. Since this document reports on the company's own share transactions and the status of its treasury shares following the termination of a buyback trust, it falls under the category of 'Transaction in Own Shares'.
2023-08-11 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Ilsung Pharmaceuticals, covering the period from January 1, 2023, to June 30, 2023. It contains comprehensive financial information, management discussion, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-11 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and contractual relationships (such as stock collateral loans) of a major shareholder (Yoon Suk-keun) in Ilsung Pharmaceuticals. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-06-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.